Skip to content
OPAGENT

Encounter closeout

In development

OpAgent Wrap is the expansion path — not the current package.

OpAgent Wrap is the expanded end-to-end clinical workflow destination: brief, listen, dictate, analyze, note completion, documentation and coding closeout, physician questions, orders and letters, procedure intent, administrative handoff, verified writeback, and downstream revenue follow-through. That complete vision is not generally available today. Wrap is a controlled expansion for practices that want OpAgent to handle more of the work surrounding each encounter.

The moment it solves

The signed note already said more than the code.

The early evidence is not a year of recovered cash. It is a measured split where the current signed note already supported a different E/M level — opportunity sitting in the chart that just closed. Realized economic value measurement is in progress.

How it works

Prepared work. Physician still decides.

  1. 01

    Start however the physician starts

    Typed, macros, dictated, or ambient. Wrap is the home, not a new documentation religion.

  2. 02

    Strengthen, then show the list

    The engine proposes; the physician verifies. Nothing files without agreement.

  3. 03

    Hand the note to coding

    CodeIQ Visit reads the signed note. Wrap does not invent a visit level on its own.

Evidence of value

Classed evidence. Not every number is cash.

EARLY MEASURED EVIDENCE

22

Analysis-split notes where the signed note already supported a higher E/M level

Opportunities detected where the current signed note already supported a different E/M. Realized economic value measurement in progress.

How this was measured

OpAgent Benchmark: count of analysis-split notes whose current signed text already supported a higher E/M level.

Sample: 22 notes in the measured split

REALIZED_VALUE is empty. Do not lead with annualized ROI. This is early measured evidence, not recovered cash.

Source: OpAgent Benchmark

EARLY MEASURED EVIDENCE

$993.30

Current-note-supported opportunity in that measured split

Fee-delta opportunity supported by the current signed note in the same 22-note split. Not recovered cash.

How this was measured

OpAgent Benchmark: contracted/labeled fee delta on the 22 notes whose signed text already supported a different E/M.

Sample: 22 notes in the measured split

Not recovered cash. REALIZED_VALUE is empty.

Source: OpAgent Benchmark

MODELED OPPORTUNITY

$18,473.76/year

Modeled single-surgeon annual figure

Selection-biased and single-surgeon. Do not lead the page with this number.

How this was measured

OpAgent Benchmark: modeled single-surgeon annualization of the measured-split opportunity.

Sample: Single surgeon

Period: Annualized from the measured split

Selection-biased, single-surgeon, REALIZED_VALUE empty. Not a lead figure and not ROI.

Source: OpAgent Benchmark

Methodology / caveat

REALIZED_VALUE is empty. The annual figure is selection-biased and single-surgeon — a modeled illustration, not a lead ROI number and not a forecast. Early measured evidence is the 22-note split, not cash recovered.

OpAgent Benchmark · Wrap · realized economic value measurement in progress

Where it connects

The rest of OpAgent is already in the room.

Request a working sessionSee Essentials